Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
AVBP
#2111
ArriVent BioPharma, Inc. Common Stock
22.9
7
+0.22%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+0.22%
Monthly Change
-1.20%
6 month change
+19.57%
Year Change
-4.01%
Previous Close
22.9
2
Open
22.9
3
Bid
Ask
Low
22.9
3
High
22.9
7
Volume
76
Markets
US Stock Market
Healthcare
AVBP
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2024
TTM
Key stats
Total common shares outstanding
34.02 M
—
Valuation ratios
Enterprise value
831.9 M
2.83 B
Price to earnings ratio
-10.41
-25.11
Price to sales ratio
—
—
Price to cash flow ratio
11.94
27.39
Price to book ratio
3.25
5.23
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
0.29
0.6
Return on equity %
0.31
0.64
Return on invested capital %
962.92
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
13.14
55.12
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
2.23
4.12
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
6.95
21.45
Net current asset value per share
7.21
27.5
Tangible book value per share
8.19
28.58
Working capital per share
6.66
25.5
Book value per share
8.19
28.58
News
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential
ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug
ArriVent BioPharma stock price target raised to $47 from $32 at Clear Street
ArriVent BioPharma’s 32% decline validates InvestingPro’s overvaluation warning
ArriVent reports 16-month PFS for lung cancer drug firmonertinib
H.C. Wainwright raises ArriVent BioPharma stock price target to $42 on NSCLC drug potential